Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

741. Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine

Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 53. 2002 Authors' objectives To provide guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine. Authors' conclusions Guidance: 1.1 Insulin glargine is recommended as a treatment option for people

2002 Health Technology Assessment (HTA) Database.

742. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials

Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients (...) with type 1 diabetes: meta-analysis of randomised controlled trials Pickup J, Mattock M, Kerry S Authors' objectives To compare glycaemic control and insulin dosage in people with type 1 diabetes who are treated by continuous subcutaneous insulin infusion (insulin infusion pump therapy) or optimised insulin injections. Searching Published trials that met the inclusion criteria were identified by searching MEDLINE (from 1975 to 2000) and EMBASE (from 1980 to 2000) for literature on insulin infusion

2002 DARE.

743. Insulins today and beyond. (Abstract)

Insulins today and beyond. The advent of insulin almost 80 years ago revolutionised treatment of diabetes and must be one of the most outstanding achievements of twentieth century medicine. Since then, there has been an ever-increasing awareness and acceptance of the need to achieve and sustain near-normoglycaemia to delay onset and retard progression of diabetic angiopathy. Physiological insulin replacement is therefore central to management of patients with diabetes who are unable to make (...) [corrected] insulin. Insulin formulations, treatment strategies, and methods and routes of delivery have changed much, with more and more options for monitoring the effect on blood glucose concentrations. Patients with type 1 and type 2 diabetes need insulin much more aggressively than previously. Parallel developments in glucose-sensing technologies are welcomed as an integral part of safe and optimum implementation of insulin replacement therapy.

2001 Lancet

744. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. (Abstract)

Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Effective glycaemic control in type 1 diabetes mellitus usually requires two or more insulin injections daily. Inhaled intrapulmonary delivery of insulin offers a potential new way to deliver meal-related insulin, eliminating the need for preprandial injections.73 patients with type 1 diabetes mellitus were studied in an open-label, proof-of-concept, parallel-group randomised trial. Patients (...) in the experimental group received preprandial inhaled insulin plus a bedtime subcutaneous ultralente insulin injection. Patients in the control group received their usual insulin regimen of two to three injections per day. Participants monitored their blood glucose four times daily, and adjusted insulin doses weekly to achieve preprandial glucose targets of 5.6-8.9 mmol/L. The primary outcome measure was change in glycosylated haemoglobin (HbA1c) after 12 weeks. Secondary outcomes were fasting and postprandial

2001 Lancet Controlled trial quality: uncertain

745. Intensive insulin therapy in critically ill patients. (Abstract)

Intensive insulin therapy in critically ill patients. Hyperglycemia and insulin resistance are common in critically ill patients, even if they have not previously had diabetes. Whether the normalization of blood glucose levels with insulin therapy improves the prognosis for such patients is not known.We performed a prospective, randomized, controlled study involving adults admitted to our surgical intensive care unit who were receiving mechanical ventilation. On admission, patients were (...) randomly assigned to receive intensive insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg per deciliter [4.4 and 6.1 mmol per liter]) or conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg per deciliter [11.9 mmol per liter] and maintenance of glucose at a level between 180 and 200 mg per deciliter [10.0 and 11.1 mmol per liter]).At 12 months, with a total of 1548 patients enrolled, intensive insulin therapy reduced mortality during

2001 NEJM Controlled trial quality: uncertain

746. Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands

Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Hutubessy R C, Vondeling H, de Sonnaville J J, Colly L P, Smit J L, Heine R J Record Status This is a critical abstract (...) for the management of patients with Type 2 diabetes initiating insulin therapy. The service consisted of a patient registration and recall system plus a laboratory. A dietician and a specific diabetes educator provided diabetes education. A supervising diabetologist could be consulted by telephone 24 hours a day. The patients were monitored at least at 3-month intervals and feedback was provided to the GP. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study

2001 NHS Economic Evaluation Database.

747. Oral and buccal insulin for diabetes - horizon scanning review

Oral and buccal insulin for diabetes - horizon scanning review Oral and buccal insulin for diabetes - horizon scanning review Oral and buccal insulin for diabetes - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Oral and buccal insulin for diabetes - horizon scanning review. Birmingham: National Horizon (...) Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001 Authors' objectives To summarise the current research evidence on oral and buccal insulin for diabetes. Authors' conclusions One buccal and three oral formulations of insulin are known to be in clinical development. There is no information on equivalence to injected insulin, long-term benefits or cost at the present time - Clinical impact: The use of oral/buccal insulin is an innovative development that may impact on the quality of life

2001 Health Technology Assessment (HTA) Database.

748. Inhaled insulin for the treatment of diabetes mellitus

Inhaled insulin for the treatment of diabetes mellitus Inhaled insulin for the treatment of diabetes mellitus Inhaled insulin for the treatment of diabetes mellitus McAuley L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McAuley L. Inhaled insulin for the treatment of diabetes mellitus. Ottawa: Canadian Coordinating Office for Health (...) Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2001: 4 Authors' objectives To summarise the available evidence on the use of inhaled insulin for the treatment of diabetes mellitus. Authors' conclusions - Insulin delivery via inhalation, as an alternative to administration by injection, is under development. - The available evidence comparing subcutaneous (sc) insulin with inhaled insulin for persons with type 1 and 2 diabetes, shows similar

2001 Health Technology Assessment (HTA) Database.

749. [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes: pharmacoeconomic analysis of cost-effectiveness]

[Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes: pharmacoeconomic analysis of cost-effectiveness] Conversion de la terapia intensiva con insulina rapida a insulina lispro en la diabetes tipo 1: analisis farmacoeconomico de coste-efectividad [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes: pharmacoeconomic analysis of cost-effectiveness] Conversion de la terapia intensiva con insulina rapida a insulina lispro en la diabetes (...) tipo 1: analisis farmacoeconomico de coste-efectividad [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes: pharmacoeconomic analysis of cost-effectiveness] Costa Pinel B, Belmonte Serrano M, Paez Vives F, Sabate Obiol A, Estopa Sanchez A, Borras Borras J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

2001 NHS Economic Evaluation Database.

750. Intensive Insulin Therapy in Critically Ill Patients

Intensive Insulin Therapy in Critically Ill Patients PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2001 PedsCCM Evidence-Based Journal Club

751. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. (Abstract)

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Oral administration of autoantigens can slow the progression of beta-cell destruction in non-obese diabetic mice. We investigated whether oral administration of recombinant human insulin could protect residual beta-cell function in recent-onset type 1 diabetes.We enrolled 131 autoantibody-positive diabetic patients aged 7-40 years (...) within 2 weeks of diagnosis (no ketoacidosis at diagnosis, weight loss <10%, polyuria for <6 weeks). They were randomly assigned 2.5 mg or 7.5 mg oral insulin daily or placebo for 1 year, in addition to subcutaneous insulin therapy. Serum C-peptide concentrations were measured in the fasting state and after stimulation, to assess beta-cell function. Autoantibodies to beta-cell antigens were assayed. Analyses were by intention to treat.Baseline C-peptide and haemoglobin A1c concentrations were similar

2000 Lancet Controlled trial quality: predicted high

752. A comparison of glyburide and insulin in women with gestational diabetes mellitus. (Abstract)

A comparison of glyburide and insulin in women with gestational diabetes mellitus. Women with gestational diabetes mellitus are rarely treated with a sulfonylurea drug, because of concern about teratogenicity and neonatal hypoglycemia. There is little information about the efficacy of these drugs in this group of women.We studied 404 women with singleton pregnancies and gestational diabetes that required treatment. The women were randomly assigned between 11 and 33 weeks of gestation to receive (...) glyburide or insulin according to an intensified treatment protocol. The primary end point was achievement of the desired level of glycemic control. Secondary end points included maternal and neonatal complications.The mean (+/-SD) pretreatment blood glucose concentration as measured at home for one week was 114+/-19 mg per deciliter (6.4+/-1.1 mmol per liter) in the glyburide group and 116+/-22 mg per deciliter (6.5+/-1.2 mmol per liter) in the insulin group (P=0.33). The mean concentrations during

2000 NEJM Controlled trial quality: uncertain

753. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Full Text available with Trip Pro

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes.Prospective, randomised, parallel group, double blind study with four week placebo run

2000 BMJ Controlled trial quality: predicted high

754. Lantus (Insulin Glargine [rDNA Origin]) Injection

Lantus (Insulin Glargine [rDNA Origin]) Injection Drug Approval Package: Lantus (Insulin Glargine [rDNA Origin]) NDA #21-081 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Lantus (Insulin Glargine [rDNA Origin]) Injection Company: Aventis Pharmaceuticals Inc. Application No.: 21-081 Approval Date: 4/20/2000 (PDF) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Correspondence (PDF) (PDF) Date created: November 20, 2001

2000 FDA - Drug Approval Package

755. Hypoglycaemia induced by exogenous insulin - 'human' and animal insulin compared

Hypoglycaemia induced by exogenous insulin - 'human' and animal insulin compared Hypoglycaemia induced by exogenous insulin - 'human' and animal insulin compared Hypoglycaemia induced by exogenous insulin - 'human' and animal insulin compared Airey C M, Williams D R, Martin P G, Bennett C M, Spoor P A Authors' objectives To compare the effects of 'human' and animal insulin on the frequency and awareness of hypoglycaemia. Searching MEDLINE (from 1975 to February 1999), EMBASE, HealthPLAN (...) Randomised controlled trials (RCTs), other comparative studies, and case series and case reports were eligible for inclusion. The studies could be of any duration. Specific interventions included in the review Studies that compared human insulin with animal insulin were eligible for inclusion. The review used the term 'human' to cover insulins produced by enzymatic modification of porcine insulin, or recombinant DNA technology. The studies could use any type of insulin in any dosage regimen. Population

2000 DARE.

756. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intensive insulin therapy for type 2 diabetes in Japan. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of Japanese patients with type 2 diabetes. Setting The setting was a hospital

2000 NHS Economic Evaluation Database.

757. Telecare of diabetic patients with intensified insulin therapy: a randomized clinical trial

Telecare of diabetic patients with intensified insulin therapy: a randomized clinical trial Telecare of diabetic patients with intensified insulin therapy: a randomized clinical trial Telecare of diabetic patients with intensified insulin therapy: a randomized clinical trial Biermann E, Dietrich W, Standl E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The technology studied was a telecare system for the monitoring and revision of insulin therapy. Patients transmitted their blood glucose readings to a diabetes centre using a modem interface. A physician then revised insulin treatment during scheduled telephone consultations with patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

2000 NHS Economic Evaluation Database.

758. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus: results from the DIGAMI study

Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus: results from the DIGAMI study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2000 NHS Economic Evaluation Database.

759. Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report)

Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report) Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report) Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report) Amate Blanco J M, Van den Eynde A M, Saz Z, Conde Olasagasti J L Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Amate Blanco J M, Van den Eynde A M, Saz Z, Conde Olasagasti J L. Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report) Madrid: Agencia de Evaluacion de Tecnologias Sanitarias (AETS). Informe de Evaluacion de Tecnologias Sanitarias No.27. 2000 Authors' objectives The goal of this report is to evaluate the efficacy of insulin infusion

2000 Health Technology Assessment (HTA) Database.

760. Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients

Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Pons JM Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pons JM (...) . Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). IN01/2000. 2000 Authors' objectives To review the available evidence on continuous subcutaneous infusion of insulin with portable pump in diabetes type I patients. Authors' conclusions Continuous subcutaneous external infusion insulin pumps were found to be effective to achieve good metabolic control, the closest

2000 Health Technology Assessment (HTA) Database.